[Hematopoietic growth factor EPO has neuro-protective and neuro-trophic effects--review].
Erythropoietin (EPO) is an acidic glycoprotein that was first detected as a hematopoietic factor and its synthesis is triggered in response to cellular hypoxia-sensing. EPO binds to type I cytokine receptors, which associate with the non-receptor tyrosine kinase Jak2, and thereby activate Stat 5a/5b, Ras/MAPK, and PI3-K/Akt signaling pathways. The recent discovery shows that there is a specific EPO/EPO-receptor system in the central nervous system (CNS), independently of the haematopoietic system. Hypoxia and anemia can up-regulate EPO/EPOR expressions in the CNS. Further studies demonstrate that EPO has substantial neuro-protective effects and acts as a neurotrophic factor on central cholinergic neurons, influencing their differentiation and regeneration. EPO also exerts neuro-protective activities in different models of brain damage in vivo and in vitro, such as hypoxia, cerebral ischaemia and sub-arachnoid haemorrhage. EPO may also be involved in synaptic plasticity via the inhibition or stimulation of various neurotransmitters. Therefore, human recombinant EPO that activate its receptors in the central nervous system might be utilized in the future clinical practice involving neuroprotection and brain repair.
Zhou
Zhuo-Yan
ZY
Department of Physiology, Medical College, Ji'nan University, Guangzhou 510632, China. zhouzhuoyan2004@yahoo.com.cn
Yang
Mo
M
Fok
Tai-Fai
TF
D000818:Animals; D001921:Brain / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D004921:Erythropoietin / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D009474:Neurons / Q000166:cytology / Q000187:drug effects; D018696:Neuroprotective Agents / Q000378:metabolism / Q000494:pharmacology; D017467:Receptors, Erythropoietin / Q000378:metabolism
D018696:Neuroprotective Agents; D017467:Receptors, Erythropoietin; D004921:Erythropoietin